Farhad Hafezi, MD PhD FARVO, is a professor of ophthalmology, anterior segment surgeon, and ocular cell biologist.
Farhad completed his medical studies at the University of Bern 1992 and then in 1993 transitioned to the University of Zurich. In 2011, Farhad conducted a fellowship in oculplastics and lids at the Rotterdam Eye Hospital and then co-founded the famous IROC AG (Zurich, Switzerland) in 2002.
From 2005-2008, Farhad completed his PhD at Erasmus University Rotterdam on the management of complications of refractive surgery while maintaining his clinical position at IROC. In 2010, Farhad became chairman of ophthalmology at the University of Geneva and director of the Geneva University Hospital Eye Clinic. In 2014, Farhad founded the ELZA Institute AG (Zurich, Switzerland), where now works clinically.
Academically, Farhad remains a professor of ophthalmology at the University of Geneva, University of Southern California and Wenzhou Medical University in China. Farhad is the group leader of the Ocular Cell Biology Laboratory at the University of Zurich.
In 2014, 2016 and 2018, he has been voted by his peers onto the biennial PowerList100, a list of the 100 most influential people in ophthalmology.
Combing patient care, research & development, and teaching, Hafezi is a pioneer and key opinion leader of corneal cross-linking (CXL).
Farhad is dedicated to humanitarian work dedicated to helping children with keratoconus by serving as an active board member of the Light for Sight Foundation. Farhad also serves on a number of industrial advisory boards, including EMAGine AG (Zug, Switzerland) that is dedicated to bringing access to CXL technology to all.